No Data
No Data
Express News | Entrada Therapeutics Inc - on Track to Initiate Elevate-45-201 Study in Q3 2025
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next
Results: Entrada Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $30
Oppenheimer Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)